株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

P-セレクチン:パイプライン製品の分析

P Selectin - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 567362
出版日 ページ情報 英文 56 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.19円で換算しております。
Back to Top
P-セレクチン:パイプライン製品の分析 P Selectin - Pipeline Review, H2 2019
出版日: 2019年12月27日 ページ情報: 英文 56 Pages
概要

当レポートでは、P-セレクチンを標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

P-セレクチン - 概要

P-セレクチン - 治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療範囲別
  • 開発中の製品:適応症別
  • 企業で開発中の製品

P-セレクチン - 治療薬の評価

  • 作用機序別
  • 投与経路別
  • 分子タイプ別

P-セレクチンの治療薬開発に従事している企業

  • Novartis AG
  • Pfizer Inc
  • Tumorend LLC

薬剤プロファイル

P-セレクチン - Dormant Products

P-セレクチン - 開発が中止された製品

P-セレクチン - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Global Blood Therapeutics Inc, H2 2019
  • Pipeline by GlycoMira Therapeutics Inc, H2 2019
  • Pipeline by Novartis AG, H2 2019
  • Pipeline by Pfizer Inc, H2 2019
  • Pipeline by Tumorend LLC, H2 2019
  • Pipeline by Vanguard Therapeutics Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC2101TDB

Summary

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) pipeline Target constitutes close to 7 molecules. The latest report P Selectin - Pipeline Review, H2 2019, outlays comprehensive information on the P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - P-selectin is a protein encoded by the SELP gene. P-selectin functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells. In unactivated endothelial cells, it is stored in granules called Weibel-Palade bodies. In unactivated platelets P-selectin is stored in alpha-granules. P-selectin plays an essential role in the initial recruitment of leukocytes (white blood cells) to the site of injury during inflammation. The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively. Report covers products from therapy areas Cardiovascular, Oncology, Ear Nose Throat Disorders, Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Hematological Disorders, Immunology, Mouth and Dental Disorders and Respiratory which include indications Vaso-Occlusive Crisis Associated With Sickle Cell Disease, Rhinosinusitis, Asthma, Chronic Kidney Disease (Chronic Renal Failure), Head And Neck Cancer, Inflammation, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Oral Mucositis, Periodontitis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Rosacea and Sickle Cell Disease.

Furthermore, this report also reviews key players involved in P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP)
  • The report reviews P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Overview
  • P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Companies Involved in Therapeutics Development
  • Global Blood Therapeutics Inc
  • GlycoMira Therapeutics Inc
  • Novartis AG
  • Pfizer Inc
  • Tumorend LLC
  • Vanguard Therapeutics Inc
  • P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Drug Profiles
  • crizanlizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GM-0111 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GM-1111 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • inclacumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pentosan polysulfate sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rivipansel sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit P and L Selectins for Inflammation and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Dormant Products
  • P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Discontinued Products
  • P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 02, 2019: Novartis to present abstract on Adakveo (crizanlizumab) at American Society of Hematology Annual Meeting & Exposition (ASH) 2019
  • Nov 18, 2019: FDA approves Novartis' Adakveo for sickle cell disease patients
  • Aug 05, 2019: Pfizer's RESET trial of rivipansel fails to meet endpoints
  • Jul 16, 2019: FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
  • May 06, 2019: GlycoMimetics announces enrollment completed for phase 3 clinical trial evaluating Rivipansel in Sickle Cell Disease
  • Jan 09, 2019: FDA grants breakthrough therapy status to crizanlizumab
  • Dec 01, 2018: Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
  • Nov 05, 2018: Novartis provides update on SEG101
  • Nov 02, 2018: Novartis to present new data on Crizanlizumab at 2018 ASH annual meeting
  • Oct 09, 2018: Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
  • Jun 14, 2018: New Hope in the Fight Against Sickle Cell Disease
  • Dec 11, 2017: Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
  • Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis
  • Dec 03, 2016: Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
  • Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top